Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Phase 3Recruiting

Lead sponsor: Merck Sharp & Dohme LLC (Industry)
Enrollment: 1,530 (estimated)
Start date: 24 Jun 2024
Primary completion: 16 Dec 2030 (estimated)
Study completion: 14 Dec 2037
Last update posted: 13 Oct 2026

Design

Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel
Masking: None
Arms: 2

Interventions

Pembrolizumab Biological
Sacituzumab tirumotecan Biological
Capecitabine Drug

Conditions and primary outcome

Triple-Negative Breast Cancer

Primary outcome

Invasive Disease-Free Survival (iDFS) (Up to ~77 months)

Posted results on ClinicalTrials.gov

Results posted on ClinicalTrials.gov: No

Results from company and journal sources

No editor-confirmed results are on record for this study.

Publications

No PubMed citation lists NCT06393374.

CT-VCA trial quality

Loading CT-VCA scores…

Data integrity

Compare what the registry, company releases, FDA documents and publications say about this study.

Drugs on HealthTrade

Sacituzumab tirumotecan

Source

NCT06393374 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read 25 Oct 2026

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.

Nothing on this page is medical or investment advice.